drugset / Trial / NCT00720109

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00720109

Phase 2/3 Completed 63 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.

Timeline

Start
2008-07-14
Primary completion
2014-12-31
Completion
2020-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule Oral
Background Cyclophosphamide Other / unclassified Intravenous
Background Cytarabine Small molecule Intrathecal
Background Daunorubicin Small molecule Intravenous
Background Dexamethasone Small molecule Intravenous
Background Etoposide Small molecule Intravenous
Background Hydrocortisone Other / unclassified Intrathecal
Background Ifosfamide Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule Oral
Background Methotrexate Small molecule Intrathecal
Background Methylprednisolone Other / unclassified Intravenous
Background Pegaspargase Protein / enzyme biologic Intramuscular
Background Prednisone Other / unclassified Oral
Background Vincristine Small molecule Intravenous
Background asparaginase Protein / enzyme biologic Intrathecal
Background filgrastim Protein / enzyme biologic Intravenous